nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Protein Kinase Inhibitors—Sunitinib—pancreatic cancer	0.507	1	CiPCiCtD
Ruxolitinib—JAK3—Erlotinib—pancreatic cancer	0.0191	0.051	CbGbCtD
Ruxolitinib—MARK2—Sunitinib—pancreatic cancer	0.0174	0.0465	CbGbCtD
Ruxolitinib—CLK2—Sunitinib—pancreatic cancer	0.0174	0.0465	CbGbCtD
Ruxolitinib—GRK7—Sunitinib—pancreatic cancer	0.0174	0.0465	CbGbCtD
Ruxolitinib—DAPK2—Sunitinib—pancreatic cancer	0.0174	0.0465	CbGbCtD
Ruxolitinib—HIPK2—Sunitinib—pancreatic cancer	0.0174	0.0465	CbGbCtD
Ruxolitinib—DAPK3—Sunitinib—pancreatic cancer	0.0174	0.0465	CbGbCtD
Ruxolitinib—DCLK3—Sunitinib—pancreatic cancer	0.0174	0.0465	CbGbCtD
Ruxolitinib—GRK1—Sunitinib—pancreatic cancer	0.0174	0.0465	CbGbCtD
Ruxolitinib—LTK—Erlotinib—pancreatic cancer	0.0152	0.0405	CbGbCtD
Ruxolitinib—LRRK2—Sunitinib—pancreatic cancer	0.0126	0.0336	CbGbCtD
Ruxolitinib—CAMK2G—Sunitinib—pancreatic cancer	0.0126	0.0336	CbGbCtD
Ruxolitinib—ROCK1—Sunitinib—pancreatic cancer	0.0126	0.0336	CbGbCtD
Ruxolitinib—TYK2—Sunitinib—pancreatic cancer	0.0126	0.0336	CbGbCtD
Ruxolitinib—DYRK1A—Sunitinib—pancreatic cancer	0.0126	0.0336	CbGbCtD
Ruxolitinib—MAST1—Sunitinib—pancreatic cancer	0.0126	0.0336	CbGbCtD
Ruxolitinib—PHKG2—Sunitinib—pancreatic cancer	0.0126	0.0336	CbGbCtD
Ruxolitinib—STK16—Sunitinib—pancreatic cancer	0.0126	0.0336	CbGbCtD
Ruxolitinib—NUAK2—Sunitinib—pancreatic cancer	0.01	0.0267	CbGbCtD
Ruxolitinib—BMP2K—Sunitinib—pancreatic cancer	0.01	0.0267	CbGbCtD
Ruxolitinib—JAK2—Sunitinib—pancreatic cancer	0.01	0.0267	CbGbCtD
Ruxolitinib—MAP3K7—Sunitinib—pancreatic cancer	0.01	0.0267	CbGbCtD
Ruxolitinib—TAOK3—Sunitinib—pancreatic cancer	0.00838	0.0223	CbGbCtD
Ruxolitinib—MAP3K3—Sunitinib—pancreatic cancer	0.00838	0.0223	CbGbCtD
Ruxolitinib—PLK4—Sunitinib—pancreatic cancer	0.00838	0.0223	CbGbCtD
Ruxolitinib—MAP3K19—Erlotinib—pancreatic cancer	0.00731	0.0195	CbGbCtD
Ruxolitinib—RET—Sunitinib—pancreatic cancer	0.00724	0.0193	CbGbCtD
Ruxolitinib—MAP3K2—Sunitinib—pancreatic cancer	0.00724	0.0193	CbGbCtD
Ruxolitinib—IRAK1—Sunitinib—pancreatic cancer	0.00724	0.0193	CbGbCtD
Ruxolitinib—MAP3K19—Sunitinib—pancreatic cancer	0.00481	0.0128	CbGbCtD
Ruxolitinib—RET—enteric nervous system—pancreatic cancer	0.00459	0.225	CbGeAlD
Ruxolitinib—PLK3—islet of Langerhans—pancreatic cancer	0.000899	0.0441	CbGeAlD
Ruxolitinib—Myelosuppression—Tamoxifen—pancreatic cancer	0.000794	0.0293	CcSEcCtD
Ruxolitinib—PRKG2—digestive system—pancreatic cancer	0.000721	0.0354	CbGeAlD
Ruxolitinib—Night sweats—Tamoxifen—pancreatic cancer	0.00069	0.0255	CcSEcCtD
Ruxolitinib—JAK1—islet of Langerhans—pancreatic cancer	0.000689	0.0338	CbGeAlD
Ruxolitinib—Myelosuppression—Sunitinib—pancreatic cancer	0.00068	0.0251	CcSEcCtD
Ruxolitinib—STK16—islet of Langerhans—pancreatic cancer	0.000647	0.0317	CbGeAlD
Ruxolitinib—PLK1—digestive system—pancreatic cancer	0.000646	0.0317	CbGeAlD
Ruxolitinib—PLK3—pancreas—pancreatic cancer	0.000632	0.031	CbGeAlD
Ruxolitinib—DAPK3—islet of Langerhans—pancreatic cancer	0.000618	0.0303	CbGeAlD
Ruxolitinib—NUAK2—islet of Langerhans—pancreatic cancer	0.000551	0.027	CbGeAlD
Ruxolitinib—Myelosuppression—Fluorouracil—pancreatic cancer	0.000536	0.0198	CcSEcCtD
Ruxolitinib—MARK2—digestive system—pancreatic cancer	0.00049	0.024	CbGeAlD
Ruxolitinib—JAK1—pancreas—pancreatic cancer	0.000485	0.0238	CbGeAlD
Ruxolitinib—CAMK1D—pancreas—pancreatic cancer	0.000473	0.0232	CbGeAlD
Ruxolitinib—TYK2—islet of Langerhans—pancreatic cancer	0.000456	0.0224	CbGeAlD
Ruxolitinib—HIPK2—pancreas—pancreatic cancer	0.000452	0.0222	CbGeAlD
Ruxolitinib—MKNK2—islet of Langerhans—pancreatic cancer	0.00045	0.0221	CbGeAlD
Ruxolitinib—IRAK1—islet of Langerhans—pancreatic cancer	0.00045	0.0221	CbGeAlD
Ruxolitinib—DAPK3—pancreas—pancreatic cancer	0.000435	0.0213	CbGeAlD
Ruxolitinib—Contusion—Tamoxifen—pancreatic cancer	0.000427	0.0158	CcSEcCtD
Ruxolitinib—JAK3—digestive system—pancreatic cancer	0.000417	0.0204	CbGeAlD
Ruxolitinib—JAK1—digestive system—pancreatic cancer	0.000414	0.0203	CbGeAlD
Ruxolitinib—DCLK1—digestive system—pancreatic cancer	0.000414	0.0203	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Tamoxifen—pancreatic cancer	0.000394	0.0145	CcSEcCtD
Ruxolitinib—Bone pain—Tamoxifen—pancreatic cancer	0.000389	0.0144	CcSEcCtD
Ruxolitinib—STK16—digestive system—pancreatic cancer	0.000388	0.0191	CbGeAlD
Ruxolitinib—NUAK2—pancreas—pancreatic cancer	0.000387	0.019	CbGeAlD
Ruxolitinib—Myelosuppression—Docetaxel—pancreatic cancer	0.000387	0.0143	CcSEcCtD
Ruxolitinib—HIPK2—digestive system—pancreatic cancer	0.000386	0.019	CbGeAlD
Ruxolitinib—Bone pain—Erlotinib—pancreatic cancer	0.000384	0.0142	CcSEcCtD
Ruxolitinib—CYP3A4—Tamoxifen—pancreatic cancer	0.000366	0.000976	CbGbCtD
Ruxolitinib—TAOK3—islet of Langerhans—pancreatic cancer	0.000364	0.0179	CbGeAlD
Ruxolitinib—CAMK2G—pancreas—pancreatic cancer	0.000363	0.0178	CbGeAlD
Ruxolitinib—ROCK1—digestive system—pancreatic cancer	0.000356	0.0175	CbGeAlD
Ruxolitinib—BMPR2—digestive system—pancreatic cancer	0.000346	0.017	CbGeAlD
Ruxolitinib—Bone pain—Sunitinib—pancreatic cancer	0.000333	0.0123	CcSEcCtD
Ruxolitinib—TYK2—pancreas—pancreatic cancer	0.00032	0.0157	CbGeAlD
Ruxolitinib—MKNK2—pancreas—pancreatic cancer	0.000316	0.0155	CbGeAlD
Ruxolitinib—IRAK1—pancreas—pancreatic cancer	0.000316	0.0155	CbGeAlD
Ruxolitinib—CYP3A4—Erlotinib—pancreatic cancer	0.000312	0.00083	CbGbCtD
Ruxolitinib—CAMK2G—digestive system—pancreatic cancer	0.00031	0.0152	CbGeAlD
Ruxolitinib—CYP3A4—Irinotecan—pancreatic cancer	0.000281	0.00075	CbGbCtD
Ruxolitinib—TYK2—digestive system—pancreatic cancer	0.000274	0.0134	CbGeAlD
Ruxolitinib—MKNK2—digestive system—pancreatic cancer	0.00027	0.0133	CbGeAlD
Ruxolitinib—DYRK1A—Topotecan—Irinotecan—pancreatic cancer	0.00027	0.17	CbGdCrCtD
Ruxolitinib—Gastrointestinal haemorrhage—Erlotinib—pancreatic cancer	0.000267	0.00988	CcSEcCtD
Ruxolitinib—Bone pain—Gemcitabine—pancreatic cancer	0.000267	0.00987	CcSEcCtD
Ruxolitinib—RET—digestive system—pancreatic cancer	0.000263	0.0129	CbGeAlD
Ruxolitinib—Myelosuppression—Epirubicin—pancreatic cancer	0.000261	0.00965	CcSEcCtD
Ruxolitinib—TAOK3—pancreas—pancreatic cancer	0.000256	0.0126	CbGeAlD
Ruxolitinib—JAK2—digestive system—pancreatic cancer	0.000249	0.0122	CbGeAlD
Ruxolitinib—Myelosuppression—Doxorubicin—pancreatic cancer	0.000242	0.00893	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Tamoxifen—pancreatic cancer	0.000238	0.00881	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Erlotinib—pancreatic cancer	0.000236	0.00872	CcSEcCtD
Ruxolitinib—Pancytopenia—Tamoxifen—pancreatic cancer	0.000222	0.0082	CcSEcCtD
Ruxolitinib—TAOK3—digestive system—pancreatic cancer	0.000219	0.0107	CbGeAlD
Ruxolitinib—Neutropenia—Tamoxifen—pancreatic cancer	0.000218	0.00807	CcSEcCtD
Ruxolitinib—Neutropenia—Erlotinib—pancreatic cancer	0.000216	0.00799	CcSEcCtD
Ruxolitinib—Weight increased—Tamoxifen—pancreatic cancer	0.000213	0.00786	CcSEcCtD
Ruxolitinib—Weight decreased—Tamoxifen—pancreatic cancer	0.000211	0.00781	CcSEcCtD
Ruxolitinib—Weight decreased—Erlotinib—pancreatic cancer	0.000209	0.00773	CcSEcCtD
Ruxolitinib—CYP3A4—Docetaxel—pancreatic cancer	0.000206	0.000549	CbGbCtD
Ruxolitinib—Infestation NOS—Erlotinib—pancreatic cancer	0.000206	0.00762	CcSEcCtD
Ruxolitinib—Infestation—Erlotinib—pancreatic cancer	0.000206	0.00762	CcSEcCtD
Ruxolitinib—CYP3A4—Sunitinib—pancreatic cancer	0.000205	0.000547	CbGbCtD
Ruxolitinib—Alanine aminotransferase increased—Sunitinib—pancreatic cancer	0.000204	0.00754	CcSEcCtD
Ruxolitinib—Urinary tract infection—Tamoxifen—pancreatic cancer	0.000202	0.00748	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Erlotinib—pancreatic cancer	0.000195	0.0072	CcSEcCtD
Ruxolitinib—Epistaxis—Erlotinib—pancreatic cancer	0.000194	0.00718	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Irinotecan—pancreatic cancer	0.000191	0.00705	CcSEcCtD
Ruxolitinib—Pancytopenia—Sunitinib—pancreatic cancer	0.00019	0.00702	CcSEcCtD
Ruxolitinib—Bone pain—Docetaxel—pancreatic cancer	0.00019	0.00701	CcSEcCtD
Ruxolitinib—Haemoglobin—Tamoxifen—pancreatic cancer	0.000188	0.00694	CcSEcCtD
Ruxolitinib—Neutropenia—Sunitinib—pancreatic cancer	0.000187	0.00691	CcSEcCtD
Ruxolitinib—Haemorrhage—Tamoxifen—pancreatic cancer	0.000187	0.00691	CcSEcCtD
Ruxolitinib—Haemoglobin—Erlotinib—pancreatic cancer	0.000186	0.00687	CcSEcCtD
Ruxolitinib—Haemorrhage—Erlotinib—pancreatic cancer	0.000185	0.00684	CcSEcCtD
Ruxolitinib—PLK1—Topotecan—Irinotecan—pancreatic cancer	0.000184	0.116	CbGdCrCtD
Ruxolitinib—PLK4—Topotecan—Irinotecan—pancreatic cancer	0.000184	0.116	CbGdCrCtD
Ruxolitinib—Gastrointestinal haemorrhage—Fluorouracil—pancreatic cancer	0.000183	0.00675	CcSEcCtD
Ruxolitinib—Weight decreased—Sunitinib—pancreatic cancer	0.000181	0.00669	CcSEcCtD
Ruxolitinib—Infestation—Sunitinib—pancreatic cancer	0.000178	0.00659	CcSEcCtD
Ruxolitinib—Infestation NOS—Sunitinib—pancreatic cancer	0.000178	0.00659	CcSEcCtD
Ruxolitinib—Urinary tract infection—Sunitinib—pancreatic cancer	0.000173	0.00641	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Sunitinib—pancreatic cancer	0.000169	0.00623	CcSEcCtD
Ruxolitinib—Epistaxis—Sunitinib—pancreatic cancer	0.000168	0.00622	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Gemcitabine—pancreatic cancer	0.000164	0.00605	CcSEcCtD
Ruxolitinib—Herpes zoster—Epirubicin—pancreatic cancer	0.000163	0.00601	CcSEcCtD
Ruxolitinib—Malnutrition—Erlotinib—pancreatic cancer	0.000161	0.00595	CcSEcCtD
Ruxolitinib—Haemoglobin—Sunitinib—pancreatic cancer	0.000161	0.00595	CcSEcCtD
Ruxolitinib—Haemorrhage—Sunitinib—pancreatic cancer	0.00016	0.00592	CcSEcCtD
Ruxolitinib—Flatulence—Erlotinib—pancreatic cancer	0.000159	0.00586	CcSEcCtD
Ruxolitinib—Neutropenia—Irinotecan—pancreatic cancer	0.000154	0.0057	CcSEcCtD
Ruxolitinib—CYP3A4—Doxorubicin—pancreatic cancer	0.000154	0.000409	CbGbCtD
Ruxolitinib—Pancytopenia—Gemcitabine—pancreatic cancer	0.000152	0.00563	CcSEcCtD
Ruxolitinib—Herpes zoster—Doxorubicin—pancreatic cancer	0.00015	0.00556	CcSEcCtD
Ruxolitinib—Anaemia—Tamoxifen—pancreatic cancer	0.00015	0.00556	CcSEcCtD
Ruxolitinib—Neutropenia—Gemcitabine—pancreatic cancer	0.00015	0.00555	CcSEcCtD
Ruxolitinib—Pancytopenia—Fluorouracil—pancreatic cancer	0.00015	0.00554	CcSEcCtD
Ruxolitinib—Weight decreased—Irinotecan—pancreatic cancer	0.000149	0.00551	CcSEcCtD
Ruxolitinib—Infestation NOS—Fluorouracil—pancreatic cancer	0.000141	0.0052	CcSEcCtD
Ruxolitinib—Infestation—Fluorouracil—pancreatic cancer	0.000141	0.0052	CcSEcCtD
Ruxolitinib—Malnutrition—Sunitinib—pancreatic cancer	0.000139	0.00515	CcSEcCtD
Ruxolitinib—Flatulence—Sunitinib—pancreatic cancer	0.000137	0.00508	CcSEcCtD
Ruxolitinib—Urinary tract infection—Fluorouracil—pancreatic cancer	0.000137	0.00506	CcSEcCtD
Ruxolitinib—Haematuria—Gemcitabine—pancreatic cancer	0.000136	0.00504	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.000136	0.00503	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Gemcitabine—pancreatic cancer	0.000135	0.005	CcSEcCtD
Ruxolitinib—Epistaxis—Fluorouracil—pancreatic cancer	0.000133	0.00491	CcSEcCtD
Ruxolitinib—Haemoglobin—Irinotecan—pancreatic cancer	0.000133	0.0049	CcSEcCtD
Ruxolitinib—Infection—Tamoxifen—pancreatic cancer	0.000132	0.00488	CcSEcCtD
Ruxolitinib—Haemorrhage—Irinotecan—pancreatic cancer	0.000132	0.00487	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Docetaxel—pancreatic cancer	0.000132	0.00487	CcSEcCtD
Ruxolitinib—Infection—Erlotinib—pancreatic cancer	0.000131	0.00483	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Tamoxifen—pancreatic cancer	0.00013	0.00481	CcSEcCtD
Ruxolitinib—Haemoglobin—Gemcitabine—pancreatic cancer	0.000129	0.00477	CcSEcCtD
Ruxolitinib—Nervous system disorder—Erlotinib—pancreatic cancer	0.000129	0.00476	CcSEcCtD
Ruxolitinib—Anaemia—Sunitinib—pancreatic cancer	0.000129	0.00476	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Erlotinib—pancreatic cancer	0.000129	0.00476	CcSEcCtD
Ruxolitinib—Haemorrhage—Gemcitabine—pancreatic cancer	0.000128	0.00475	CcSEcCtD
Ruxolitinib—Bone pain—Epirubicin—pancreatic cancer	0.000128	0.00472	CcSEcCtD
Ruxolitinib—Skin disorder—Erlotinib—pancreatic cancer	0.000128	0.00472	CcSEcCtD
Ruxolitinib—Haemoglobin—Fluorouracil—pancreatic cancer	0.000127	0.00469	CcSEcCtD
Ruxolitinib—Haemorrhage—Fluorouracil—pancreatic cancer	0.000126	0.00467	CcSEcCtD
Ruxolitinib—Bone pain—Doxorubicin—pancreatic cancer	0.000118	0.00437	CcSEcCtD
Ruxolitinib—CAMK2G—Azacitidine—Gemcitabine—pancreatic cancer	0.000118	0.0744	CbGdCrCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.000118	0.00436	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Docetaxel—pancreatic cancer	0.000116	0.0043	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.000115	0.00424	CcSEcCtD
Ruxolitinib—Fatigue—Tamoxifen—pancreatic cancer	0.000115	0.00423	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000113	0.00419	CcSEcCtD
Ruxolitinib—Fatigue—Erlotinib—pancreatic cancer	0.000113	0.00419	CcSEcCtD
Ruxolitinib—Flatulence—Irinotecan—pancreatic cancer	0.000113	0.00418	CcSEcCtD
Ruxolitinib—Infection—Sunitinib—pancreatic cancer	0.000113	0.00418	CcSEcCtD
Ruxolitinib—Nervous system disorder—Sunitinib—pancreatic cancer	0.000112	0.00412	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Sunitinib—pancreatic cancer	0.000111	0.00412	CcSEcCtD
Ruxolitinib—Skin disorder—Sunitinib—pancreatic cancer	0.00011	0.00408	CcSEcCtD
Ruxolitinib—Pancytopenia—Docetaxel—pancreatic cancer	0.000108	0.004	CcSEcCtD
Ruxolitinib—Neutropenia—Docetaxel—pancreatic cancer	0.000107	0.00394	CcSEcCtD
Ruxolitinib—Anaemia—Irinotecan—pancreatic cancer	0.000106	0.00392	CcSEcCtD
Ruxolitinib—Body temperature increased—Erlotinib—pancreatic cancer	0.000104	0.00384	CcSEcCtD
Ruxolitinib—Weight increased—Docetaxel—pancreatic cancer	0.000104	0.00383	CcSEcCtD
Ruxolitinib—Anaemia—Gemcitabine—pancreatic cancer	0.000103	0.00382	CcSEcCtD
Ruxolitinib—Weight decreased—Docetaxel—pancreatic cancer	0.000103	0.00381	CcSEcCtD
Ruxolitinib—Anaemia—Fluorouracil—pancreatic cancer	0.000102	0.00376	CcSEcCtD
Ruxolitinib—Infestation—Docetaxel—pancreatic cancer	0.000102	0.00375	CcSEcCtD
Ruxolitinib—Infestation NOS—Docetaxel—pancreatic cancer	0.000102	0.00375	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Sunitinib—pancreatic cancer	9.82e-05	0.00363	CcSEcCtD
Ruxolitinib—Fatigue—Sunitinib—pancreatic cancer	9.81e-05	0.00362	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Docetaxel—pancreatic cancer	9.61e-05	0.00355	CcSEcCtD
Ruxolitinib—Epistaxis—Docetaxel—pancreatic cancer	9.58e-05	0.00354	CcSEcCtD
Ruxolitinib—Asthenia—Tamoxifen—pancreatic cancer	9.53e-05	0.00352	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	9.46e-05	0.0035	CcSEcCtD
Ruxolitinib—Asthenia—Erlotinib—pancreatic cancer	9.43e-05	0.00348	CcSEcCtD
Ruxolitinib—Pruritus—Tamoxifen—pancreatic cancer	9.4e-05	0.00347	CcSEcCtD
Ruxolitinib—Infection—Irinotecan—pancreatic cancer	9.31e-05	0.00344	CcSEcCtD
Ruxolitinib—Pruritus—Erlotinib—pancreatic cancer	9.3e-05	0.00344	CcSEcCtD
Ruxolitinib—Nervous system disorder—Irinotecan—pancreatic cancer	9.19e-05	0.0034	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Irinotecan—pancreatic cancer	9.17e-05	0.00339	CcSEcCtD
Ruxolitinib—Haemoglobin—Docetaxel—pancreatic cancer	9.16e-05	0.00339	CcSEcCtD
Ruxolitinib—Haemorrhage—Docetaxel—pancreatic cancer	9.12e-05	0.00337	CcSEcCtD
Ruxolitinib—Infection—Gemcitabine—pancreatic cancer	9.07e-05	0.00335	CcSEcCtD
Ruxolitinib—Body temperature increased—Sunitinib—pancreatic cancer	8.99e-05	0.00332	CcSEcCtD
Ruxolitinib—Nervous system disorder—Gemcitabine—pancreatic cancer	8.95e-05	0.00331	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Gemcitabine—pancreatic cancer	8.94e-05	0.0033	CcSEcCtD
Ruxolitinib—Infection—Fluorouracil—pancreatic cancer	8.92e-05	0.0033	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—pancreatic cancer	8.89e-05	0.00329	CcSEcCtD
Ruxolitinib—Skin disorder—Gemcitabine—pancreatic cancer	8.87e-05	0.00328	CcSEcCtD
Ruxolitinib—Nervous system disorder—Fluorouracil—pancreatic cancer	8.8e-05	0.00325	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Fluorouracil—pancreatic cancer	8.79e-05	0.00325	CcSEcCtD
Ruxolitinib—Dizziness—Tamoxifen—pancreatic cancer	8.78e-05	0.00325	CcSEcCtD
Ruxolitinib—Dizziness—Erlotinib—pancreatic cancer	8.69e-05	0.00321	CcSEcCtD
Ruxolitinib—Headache—Tamoxifen—pancreatic cancer	8.32e-05	0.00308	CcSEcCtD
Ruxolitinib—Headache—Erlotinib—pancreatic cancer	8.23e-05	0.00304	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—pancreatic cancer	8.22e-05	0.00304	CcSEcCtD
Ruxolitinib—Asthenia—Sunitinib—pancreatic cancer	8.16e-05	0.00302	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Irinotecan—pancreatic cancer	8.09e-05	0.00299	CcSEcCtD
Ruxolitinib—Fatigue—Irinotecan—pancreatic cancer	8.08e-05	0.00299	CcSEcCtD
Ruxolitinib—Pruritus—Sunitinib—pancreatic cancer	8.05e-05	0.00297	CcSEcCtD
Ruxolitinib—Malnutrition—Docetaxel—pancreatic cancer	7.94e-05	0.00293	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	7.88e-05	0.00291	CcSEcCtD
Ruxolitinib—Fatigue—Gemcitabine—pancreatic cancer	7.87e-05	0.00291	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	7.84e-05	0.0029	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	7.75e-05	0.00286	CcSEcCtD
Ruxolitinib—Dizziness—Sunitinib—pancreatic cancer	7.52e-05	0.00278	CcSEcCtD
Ruxolitinib—Body temperature increased—Irinotecan—pancreatic cancer	7.41e-05	0.00274	CcSEcCtD
Ruxolitinib—Anaemia—Docetaxel—pancreatic cancer	7.34e-05	0.00271	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—pancreatic cancer	7.3e-05	0.0027	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	7.25e-05	0.00268	CcSEcCtD
Ruxolitinib—Body temperature increased—Gemcitabine—pancreatic cancer	7.22e-05	0.00267	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—pancreatic cancer	7.18e-05	0.00266	CcSEcCtD
Ruxolitinib—Headache—Sunitinib—pancreatic cancer	7.13e-05	0.00263	CcSEcCtD
Ruxolitinib—Body temperature increased—Fluorouracil—pancreatic cancer	7.09e-05	0.00262	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—pancreatic cancer	6.99e-05	0.00258	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—pancreatic cancer	6.95e-05	0.00257	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—pancreatic cancer	6.85e-05	0.00253	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—pancreatic cancer	6.85e-05	0.00253	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—pancreatic cancer	6.75e-05	0.0025	CcSEcCtD
Ruxolitinib—Asthenia—Irinotecan—pancreatic cancer	6.72e-05	0.00248	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	6.71e-05	0.00248	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—pancreatic cancer	6.66e-05	0.00246	CcSEcCtD
Ruxolitinib—CYP3A4—digestive system—pancreatic cancer	6.65e-05	0.00326	CbGeAlD
Ruxolitinib—Neutropenia—Doxorubicin—pancreatic cancer	6.65e-05	0.00246	CcSEcCtD
Ruxolitinib—Asthenia—Gemcitabine—pancreatic cancer	6.55e-05	0.00242	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—pancreatic cancer	6.53e-05	0.00241	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	6.48e-05	0.00239	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—pancreatic cancer	6.47e-05	0.00239	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—pancreatic cancer	6.46e-05	0.00239	CcSEcCtD
Ruxolitinib—Pruritus—Gemcitabine—pancreatic cancer	6.46e-05	0.00239	CcSEcCtD
Ruxolitinib—Infection—Docetaxel—pancreatic cancer	6.44e-05	0.00238	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—pancreatic cancer	6.43e-05	0.00238	CcSEcCtD
Ruxolitinib—Nervous system disorder—Docetaxel—pancreatic cancer	6.35e-05	0.00235	CcSEcCtD
Ruxolitinib—Pruritus—Fluorouracil—pancreatic cancer	6.35e-05	0.00235	CcSEcCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—pancreatic cancer	6.35e-05	0.04	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—pancreatic cancer	6.35e-05	0.04	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—pancreatic cancer	6.35e-05	0.04	CbGdCrCtD
Ruxolitinib—Thrombocytopenia—Docetaxel—pancreatic cancer	6.34e-05	0.00234	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—pancreatic cancer	6.34e-05	0.00234	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—pancreatic cancer	6.34e-05	0.00234	CcSEcCtD
Ruxolitinib—Skin disorder—Docetaxel—pancreatic cancer	6.29e-05	0.00233	CcSEcCtD
Ruxolitinib—Dizziness—Irinotecan—pancreatic cancer	6.2e-05	0.00229	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—pancreatic cancer	6.18e-05	0.00228	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—pancreatic cancer	6.16e-05	0.00228	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—pancreatic cancer	6.15e-05	0.00227	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—pancreatic cancer	6.04e-05	0.00223	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	5.99e-05	0.00222	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—pancreatic cancer	5.98e-05	0.00221	CcSEcCtD
Ruxolitinib—Dizziness—Fluorouracil—pancreatic cancer	5.93e-05	0.00219	CcSEcCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—pancreatic cancer	5.87e-05	0.037	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—pancreatic cancer	5.87e-05	0.037	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—pancreatic cancer	5.87e-05	0.037	CbGdCrCtD
Ruxolitinib—Headache—Irinotecan—pancreatic cancer	5.87e-05	0.00217	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—pancreatic cancer	5.72e-05	0.00211	CcSEcCtD
Ruxolitinib—Headache—Gemcitabine—pancreatic cancer	5.72e-05	0.00211	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—pancreatic cancer	5.69e-05	0.0021	CcSEcCtD
Ruxolitinib—Headache—Fluorouracil—pancreatic cancer	5.62e-05	0.00208	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	5.59e-05	0.00207	CcSEcCtD
Ruxolitinib—Fatigue—Docetaxel—pancreatic cancer	5.58e-05	0.00206	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—pancreatic cancer	5.35e-05	0.00198	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—pancreatic cancer	5.27e-05	0.00195	CcSEcCtD
Ruxolitinib—Body temperature increased—Docetaxel—pancreatic cancer	5.12e-05	0.00189	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—pancreatic cancer	4.95e-05	0.00183	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—pancreatic cancer	4.95e-05	0.00183	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—pancreatic cancer	4.88e-05	0.0018	CcSEcCtD
Ruxolitinib—PLK1—Cytarabine—Gemcitabine—pancreatic cancer	4.68e-05	0.0295	CbGdCrCtD
Ruxolitinib—Asthenia—Docetaxel—pancreatic cancer	4.65e-05	0.00172	CcSEcCtD
Ruxolitinib—Pruritus—Docetaxel—pancreatic cancer	4.58e-05	0.00169	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—pancreatic cancer	4.58e-05	0.00169	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	4.53e-05	0.00167	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—pancreatic cancer	4.34e-05	0.0016	CcSEcCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—pancreatic cancer	4.34e-05	0.0273	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—pancreatic cancer	4.34e-05	0.0273	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—pancreatic cancer	4.34e-05	0.0273	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—pancreatic cancer	4.34e-05	0.0273	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—pancreatic cancer	4.34e-05	0.0273	CbGdCrCtD
Ruxolitinib—Nervous system disorder—Epirubicin—pancreatic cancer	4.28e-05	0.00158	CcSEcCtD
Ruxolitinib—Dizziness—Docetaxel—pancreatic cancer	4.28e-05	0.00158	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—pancreatic cancer	4.28e-05	0.00158	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—pancreatic cancer	4.24e-05	0.00157	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	4.19e-05	0.00155	CcSEcCtD
Ruxolitinib—Headache—Docetaxel—pancreatic cancer	4.06e-05	0.0015	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—pancreatic cancer	4.02e-05	0.00148	CcSEcCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—pancreatic cancer	4.01e-05	0.0253	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—pancreatic cancer	4.01e-05	0.0253	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—pancreatic cancer	4.01e-05	0.0253	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—pancreatic cancer	4.01e-05	0.0253	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—pancreatic cancer	4.01e-05	0.0253	CbGdCrCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—pancreatic cancer	3.96e-05	0.00147	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.96e-05	0.00146	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—pancreatic cancer	3.93e-05	0.00145	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.77e-05	0.00139	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—pancreatic cancer	3.77e-05	0.00139	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.49e-05	0.00129	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—pancreatic cancer	3.49e-05	0.00129	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—pancreatic cancer	3.45e-05	0.00128	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—pancreatic cancer	3.2e-05	0.00118	CcSEcCtD
Ruxolitinib—Asthenia—Epirubicin—pancreatic cancer	3.13e-05	0.00116	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—pancreatic cancer	3.09e-05	0.00114	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—pancreatic cancer	2.9e-05	0.00107	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—pancreatic cancer	2.89e-05	0.00107	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—pancreatic cancer	2.86e-05	0.00106	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—pancreatic cancer	2.74e-05	0.00101	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—pancreatic cancer	2.67e-05	0.000988	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—pancreatic cancer	2.53e-05	0.000936	CcSEcCtD
Ruxolitinib—JAK3—Signaling Pathways—SRC—pancreatic cancer	1.02e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—pancreatic cancer	1.01e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—pancreatic cancer	1.01e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGF—pancreatic cancer	1.01e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CASP3—pancreatic cancer	1e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CD—pancreatic cancer	9.99e-07	1.47e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—SRC—pancreatic cancer	9.98e-07	1.46e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—pancreatic cancer	9.96e-07	1.46e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—pancreatic cancer	9.95e-07	1.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTEN—pancreatic cancer	9.93e-07	1.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL8—pancreatic cancer	9.92e-07	1.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—pancreatic cancer	9.91e-07	1.46e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—STAT3—pancreatic cancer	9.91e-07	1.45e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—pancreatic cancer	9.89e-07	1.45e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NRAS—pancreatic cancer	9.89e-07	1.45e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PIK3CA—pancreatic cancer	9.87e-07	1.45e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP3—pancreatic cancer	9.86e-07	1.45e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—STAT3—pancreatic cancer	9.79e-07	1.44e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NRAS—pancreatic cancer	9.77e-07	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—pancreatic cancer	9.76e-07	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—pancreatic cancer	9.76e-07	1.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—SRC—pancreatic cancer	9.68e-07	1.42e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CTNNB1—pancreatic cancer	9.67e-07	1.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—STAT3—pancreatic cancer	9.62e-07	1.41e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—pancreatic cancer	9.6e-07	1.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NRAS—pancreatic cancer	9.6e-07	1.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—pancreatic cancer	9.57e-07	1.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CD—pancreatic cancer	9.51e-07	1.4e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—pancreatic cancer	9.51e-07	1.4e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CTNNB1—pancreatic cancer	9.51e-07	1.4e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—pancreatic cancer	9.49e-07	1.39e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—pancreatic cancer	9.48e-07	1.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TERT—pancreatic cancer	9.45e-07	1.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CB—pancreatic cancer	9.43e-07	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTEN—pancreatic cancer	9.42e-07	1.38e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—pancreatic cancer	9.33e-07	1.37e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—pancreatic cancer	9.32e-07	1.37e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NRAS—pancreatic cancer	9.31e-07	1.37e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ARG2—pancreatic cancer	9.28e-07	1.36e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTEN—pancreatic cancer	9.27e-07	1.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CD—pancreatic cancer	9.23e-07	1.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—SRC—pancreatic cancer	9.21e-07	1.35e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—pancreatic cancer	9.19e-07	1.35e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—pancreatic cancer	9.15e-07	1.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—pancreatic cancer	9.14e-07	1.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—pancreatic cancer	9.13e-07	1.34e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—pancreatic cancer	9.1e-07	1.34e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—pancreatic cancer	9.08e-07	1.33e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—pancreatic cancer	9.04e-07	1.33e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—pancreatic cancer	9.04e-07	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HIF1A—pancreatic cancer	9.04e-07	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TSC2—pancreatic cancer	9.01e-07	1.32e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—pancreatic cancer	9.01e-07	1.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—pancreatic cancer	8.96e-07	1.32e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CD—pancreatic cancer	8.96e-07	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—pancreatic cancer	8.9e-07	1.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—pancreatic cancer	8.88e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—pancreatic cancer	8.86e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—pancreatic cancer	8.86e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—pancreatic cancer	8.82e-07	1.29e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—pancreatic cancer	8.78e-07	1.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—pancreatic cancer	8.74e-07	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SRC—pancreatic cancer	8.74e-07	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CB—pancreatic cancer	8.71e-07	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KDR—pancreatic cancer	8.64e-07	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—pancreatic cancer	8.63e-07	1.27e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SRC—pancreatic cancer	8.59e-07	1.26e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—pancreatic cancer	8.51e-07	1.25e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—pancreatic cancer	8.51e-07	1.25e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—pancreatic cancer	8.48e-07	1.24e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—pancreatic cancer	8.47e-07	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—pancreatic cancer	8.43e-07	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—pancreatic cancer	8.41e-07	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—pancreatic cancer	8.4e-07	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—pancreatic cancer	8.4e-07	1.23e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—pancreatic cancer	8.37e-07	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—pancreatic cancer	8.36e-07	1.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—pancreatic cancer	8.31e-07	1.22e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CB—pancreatic cancer	8.29e-07	1.22e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—pancreatic cancer	8.29e-07	1.22e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—pancreatic cancer	8.27e-07	1.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—pancreatic cancer	8.26e-07	1.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—pancreatic cancer	8.25e-07	1.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—pancreatic cancer	8.23e-07	1.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NFKBIA—pancreatic cancer	8.22e-07	1.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—pancreatic cancer	8.15e-07	1.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH1—pancreatic cancer	8.14e-07	1.19e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMP—pancreatic cancer	8.11e-07	1.19e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—pancreatic cancer	8.07e-07	1.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—pancreatic cancer	8.07e-07	1.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CB—pancreatic cancer	8.05e-07	1.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—pancreatic cancer	8.01e-07	1.18e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—pancreatic cancer	7.97e-07	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—pancreatic cancer	7.96e-07	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—pancreatic cancer	7.96e-07	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGF—pancreatic cancer	7.87e-07	1.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—pancreatic cancer	7.83e-07	1.15e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—pancreatic cancer	7.82e-07	1.15e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—pancreatic cancer	7.81e-07	1.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CB—pancreatic cancer	7.81e-07	1.15e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—pancreatic cancer	7.75e-07	1.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—pancreatic cancer	7.73e-07	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—pancreatic cancer	7.73e-07	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—pancreatic cancer	7.72e-07	1.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—pancreatic cancer	7.7e-07	1.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—pancreatic cancer	7.68e-07	1.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—pancreatic cancer	7.68e-07	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—pancreatic cancer	7.66e-07	1.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—pancreatic cancer	7.63e-07	1.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—pancreatic cancer	7.63e-07	1.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—pancreatic cancer	7.59e-07	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SRC—pancreatic cancer	7.56e-07	1.11e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—pancreatic cancer	7.53e-07	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—pancreatic cancer	7.53e-07	1.1e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—pancreatic cancer	7.5e-07	1.1e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—pancreatic cancer	7.48e-07	1.1e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—pancreatic cancer	7.47e-07	1.1e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—pancreatic cancer	7.42e-07	1.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—pancreatic cancer	7.4e-07	1.09e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—pancreatic cancer	7.36e-07	1.08e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—pancreatic cancer	7.35e-07	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—pancreatic cancer	7.29e-07	1.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—pancreatic cancer	7.27e-07	1.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—pancreatic cancer	7.25e-07	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—pancreatic cancer	7.23e-07	1.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—pancreatic cancer	7.23e-07	1.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—pancreatic cancer	7.21e-07	1.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—pancreatic cancer	7.21e-07	1.06e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—pancreatic cancer	7.18e-07	1.05e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—pancreatic cancer	7.16e-07	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—pancreatic cancer	7.15e-07	1.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—pancreatic cancer	7.14e-07	1.05e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—pancreatic cancer	7.11e-07	1.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—pancreatic cancer	7.02e-07	1.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—pancreatic cancer	7.01e-07	1.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CD—pancreatic cancer	7e-07	1.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—pancreatic cancer	7e-07	1.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—pancreatic cancer	6.99e-07	1.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SRC—pancreatic cancer	6.98e-07	1.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—pancreatic cancer	6.95e-07	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.93e-07	1.02e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—pancreatic cancer	6.92e-07	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—pancreatic cancer	6.85e-07	1.01e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—pancreatic cancer	6.81e-07	1e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—pancreatic cancer	6.78e-07	9.96e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—pancreatic cancer	6.78e-07	9.96e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—pancreatic cancer	6.75e-07	9.9e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—pancreatic cancer	6.73e-07	9.88e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—pancreatic cancer	6.71e-07	9.86e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—pancreatic cancer	6.65e-07	9.76e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SRC—pancreatic cancer	6.64e-07	9.75e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—pancreatic cancer	6.63e-07	9.73e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	6.54e-07	9.6e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—pancreatic cancer	6.54e-07	9.6e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—pancreatic cancer	6.48e-07	9.52e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—pancreatic cancer	6.47e-07	9.5e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SRC—pancreatic cancer	6.45e-07	9.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DPYD—pancreatic cancer	6.43e-07	9.44e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—pancreatic cancer	6.43e-07	9.44e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—pancreatic cancer	6.41e-07	9.41e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—pancreatic cancer	6.39e-07	9.38e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—pancreatic cancer	6.39e-07	9.37e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—pancreatic cancer	6.32e-07	9.28e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—pancreatic cancer	6.31e-07	9.26e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—pancreatic cancer	6.29e-07	9.24e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—pancreatic cancer	6.28e-07	9.22e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—pancreatic cancer	6.26e-07	9.19e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SRC—pancreatic cancer	6.26e-07	9.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—pancreatic cancer	6.25e-07	9.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—pancreatic cancer	6.24e-07	9.16e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—pancreatic cancer	6.22e-07	9.13e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—pancreatic cancer	6.2e-07	9.11e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—pancreatic cancer	6.2e-07	9.1e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—pancreatic cancer	6.15e-07	9.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—pancreatic cancer	6.12e-07	8.98e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	6.1e-07	8.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CB—pancreatic cancer	6.1e-07	8.95e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—pancreatic cancer	6.09e-07	8.94e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—pancreatic cancer	6.05e-07	8.88e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—pancreatic cancer	6.03e-07	8.86e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—pancreatic cancer	6.02e-07	8.83e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—pancreatic cancer	6.01e-07	8.83e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—pancreatic cancer	5.95e-07	8.74e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—pancreatic cancer	5.94e-07	8.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—pancreatic cancer	5.86e-07	8.6e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—pancreatic cancer	5.82e-07	8.55e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—pancreatic cancer	5.82e-07	8.55e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—pancreatic cancer	5.78e-07	8.48e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—pancreatic cancer	5.78e-07	8.48e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—pancreatic cancer	5.77e-07	8.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—pancreatic cancer	5.75e-07	8.44e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—pancreatic cancer	5.72e-07	8.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—pancreatic cancer	5.66e-07	8.31e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—pancreatic cancer	5.65e-07	8.3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—pancreatic cancer	5.61e-07	8.24e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—pancreatic cancer	5.61e-07	8.23e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—pancreatic cancer	5.59e-07	8.21e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—pancreatic cancer	5.5e-07	8.08e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—pancreatic cancer	5.48e-07	8.05e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—pancreatic cancer	5.46e-07	8.02e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—pancreatic cancer	5.43e-07	7.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—pancreatic cancer	5.41e-07	7.94e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—pancreatic cancer	5.34e-07	7.84e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—pancreatic cancer	5.34e-07	7.84e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—pancreatic cancer	5.32e-07	7.81e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—pancreatic cancer	5.31e-07	7.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—pancreatic cancer	5.3e-07	7.78e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—pancreatic cancer	5.27e-07	7.74e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—pancreatic cancer	5.18e-07	7.6e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—pancreatic cancer	5.14e-07	7.55e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—pancreatic cancer	5.05e-07	7.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—pancreatic cancer	4.91e-07	7.21e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—pancreatic cancer	4.91e-07	7.2e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—pancreatic cancer	4.89e-07	7.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SRC—pancreatic cancer	4.89e-07	7.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—pancreatic cancer	4.76e-07	6.99e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—pancreatic cancer	4.76e-07	6.99e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—pancreatic cancer	4.75e-07	6.97e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CD44—pancreatic cancer	4.73e-07	6.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—pancreatic cancer	4.71e-07	6.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—pancreatic cancer	4.7e-07	6.9e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—pancreatic cancer	4.7e-07	6.9e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—pancreatic cancer	4.68e-07	6.86e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—pancreatic cancer	4.6e-07	6.76e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—pancreatic cancer	4.54e-07	6.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCG—pancreatic cancer	4.53e-07	6.65e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—pancreatic cancer	4.4e-07	6.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—pancreatic cancer	4.38e-07	6.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—pancreatic cancer	4.37e-07	6.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—pancreatic cancer	4.34e-07	6.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—pancreatic cancer	4.28e-07	6.29e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—STK11—pancreatic cancer	4.26e-07	6.26e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—pancreatic cancer	4.13e-07	6.06e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—pancreatic cancer	4.05e-07	5.94e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—pancreatic cancer	4.01e-07	5.88e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—pancreatic cancer	3.89e-07	5.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—pancreatic cancer	3.72e-07	5.46e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.67e-07	5.38e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—pancreatic cancer	3.6e-07	5.28e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—pancreatic cancer	3.44e-07	5.05e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—pancreatic cancer	3.04e-07	4.46e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—pancreatic cancer	2.98e-07	4.38e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.69e-07	3.95e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.6e-07	3.81e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.37e-07	3.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.06e-07	3.03e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.04e-07	3e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.78e-07	2.62e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.26e-07	1.84e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.03e-07	1.51e-06	CbGpPWpGaD
